Why does acyclovir show selective activity against HSV-infected cells rather than harming healthy cells broadly?
Choose an answer, then check it.
Clinical Pharmacology · Antiviral Medications
Herpesvirus Medications
On this page 6 sections
In 30 seconds
Herpesvirus antivirals do not cure infection — they suppress viral replication so outbreaks resolve faster and complications drop, while the virus stays latent in nerve tissue and can reactivate later. Acyclovir and its prodrug valacyclovir (plus famciclovir and penciclovir) treat herpes simplex, varicella, and zoster, working best when started at the first sign of an outbreak. Ganciclovir/valganciclovir, foscarnet, cidofovir, and letermovir target cytomegalovirus, mainly in immunocompromised and transplant patients, each carrying a distinct toxicity that requires monitoring.
The college version
Suppression, Not Cure
Herpesviruses — herpes simplex virus (HSV-1, HSV-2), varicella-zoster virus (VZV), and cytomegalovirus (CMV) — establish lifelong latency in nerve ganglia or other host cells after initial infection. Antivirals block active viral DNA replication but cannot reach or eliminate this latent reservoir, so recurrence remains possible. Because these drugs slow replication already underway, timing matters: starting therapy within the first day or two of symptoms shortens outbreak duration, reduces viral shedding, and lowers complication risk far more than starting after lesions are fully established.
The Guanosine Analog Family
Acyclovir is the prototype agent. It is a guanosine analog requiring three phosphorylation steps to activate, but the crucial first step depends on viral thymidine kinase, an enzyme HSV and VZV produce far more efficiently than human cells do. This means acyclovir is activated mainly inside infected cells, giving it excellent selectivity — a classic example of exploiting a pathogen-specific enzyme. Once fully phosphorylated, it competes with the natural substrate for viral DNA polymerase and terminates the growing DNA chain.
Valacyclovir is the prodrug of acyclovir; better gut absorption lets it achieve higher blood levels with less frequent dosing. Famciclovir is the prodrug of penciclovir, which works by the same thymidine-kinase-dependent mechanism and fills a similar clinical role, particularly for herpes zoster.
Indications
These agents treat orolabial herpes (cold sores), genital herpes, herpes encephalitis, and neonatal herpes — a severe, potentially fatal infection acquired around delivery. They also treat varicella (chickenpox) and herpes zoster (shingles); for zoster, early treatment is especially valuable because it lowers the risk and severity of postherpetic neuralgia, the persistent nerve pain that can linger after the rash resolves. Chronic suppressive therapy is also used for patients with frequent recurrent genital herpes, reducing outbreak frequency and transmission risk.
Adverse Effects and Nursing Considerations
Oral acyclovir and valacyclovir commonly cause nausea and headache. More serious concerns arise with intravenous acyclovir: because the drug can crystallize in renal tubules, crystalline nephropathy is a known risk, so adequate hydration and slow infusion are essential precautions. Neurotoxicity — confusion, agitation, and myoclonus — can occur, particularly with renal impairment, since the drug is renally cleared and accumulates when kidneys filter poorly. Dose adjustment based on renal function is a standard safeguard across this drug class.
CMV-Directed Agents
Cytomegalovirus lacks the same thymidine kinase target, so different agents are needed. Ganciclovir and its oral prodrug valganciclovir are first-line for CMV, but their dominant toxicity is myelosuppression — suppressed production of white cells, red cells, and platelets — requiring blood count monitoring. Foscarnet and cidofovir are second-line, reserved for resistant CMV or when myelosuppression precludes ganciclovir. Both carry significant nephrotoxicity risk, and foscarnet additionally disturbs electrolytes, particularly calcium and magnesium, which can provoke seizures or cardiac effects if unrecognized.
Prevention Strategies
Letermovir is used for CMV prophylaxis in stem cell transplant recipients, preventing reactivation during the vulnerable post-transplant period without ganciclovir's marrow-suppressing burden. More broadly, varicella and zoster vaccines reduce the incidence and severity of chickenpox and shingles, representing the most effective strategy overall: preventing infection or reactivation rather than treating it afterward.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Imagine these viruses are like a sneaky animal that burrows into a tunnel underground and goes to sleep — it never fully leaves, it just naps until it wakes back up. The medicines can't dig it out of its tunnel, but when it wakes up and starts causing trouble, the medicine acts like a roadblock that stops it from making copies of itself, so the trouble stops faster and doesn't spread as far. Acyclovir is clever because it only gets "switched on" by a special key that only infected cells have, so it mostly leaves healthy cells alone. Some of these medicines are tough on the kidneys or the blood-making factory in your bones, so doctors watch those closely, like checking the oil and water in a car so it doesn't overheat while working hard.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient with shingles delays starting antiviral therapy for over a week after the rash appears. How might this affect their risk of postherpetic neuralgia, and why?
Show answer
Delayed treatment likely raises the risk
Starting antivirals early is what helps lower the risk and severity of postherpetic neuralgia, so waiting more than a week misses the window where treatment does the most good, leaving a higher chance of lingering nerve pain after the rash clears.
A nurse notes that a patient receiving IV acyclovir has reduced kidney function. What two related concerns should this raise regarding the drug's dosing and monitoring?
Show answer
Reduced clearance and neurotoxicity risk
Since acyclovir leaves the body through the kidneys, poor kidney function lets the drug build up, raising the risk of neurotoxicity like confusion or myoclonus — so the dose typically needs adjustment downward and the patient should be watched closely for these neurologic signs.
Quick check
3 questions here. Answers stay hidden until you check.
Which adverse effect is most closely associated with intravenous acyclovir specifically, requiring hydration and slow infusion to prevent it?
Choose an answer, then check it.
What is the dominant, dose-limiting toxicity of ganciclovir and valganciclovir?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.